Cancer Drugs Market

The growth of the global oncology/cancer drugs market is primarily driven by an increase in the occurrence of various cancer disorders, a rise in the popularity of innovative therapies and an increase in the global geriatric population. The market is expected to expand due to increased cancer awareness and the availability of cancer drugs. On the other hand, the high cost of new drug production, combined with the risk of failure and side effects associated with cancer drug therapies, is expected to limit market growth. The increased number of pipeline products and the high potential of emerging economies are expected to create new opportunities for market players in the future.

• By depending on type of drug class, the targeted therapy occupied 56% share of the global oncology drugs market in 2019.
• By depending on indication, the lung cancer segment anticipates growth with the highest CAGR throughout the forecast period.
• By region, the Asia-Pacific oncology drugs market is anticipated to exhibit a CAGR of 9.4% during the forecast period.